Welcome to our dedicated page for Humacyte SEC filings (Ticker: HUMAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Humacyte's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Humacyte's regulatory disclosures and financial reporting.
Humacyte, Inc. CFO and Chief Corporate Development Officer Dale A. Sander reported an automated sale of 45,887 shares of common stock at an average price of $0.8967 per share. The sale was executed solely to cover statutory tax withholding from vested restricted stock units under a pre-arranged Rule 10b5-1 sell-to-cover plan, not as a discretionary sale. After this transaction, he holds 267,213 shares directly and 40,600 shares indirectly through his spouse.
Humacyte, Inc.'s Chief Medical Officer, Shamik J. Parikh, reported an automated sale of 45,887 shares of common stock at an average price of $0.8967 per share.
The filing explains this was a mandatory “sell-to-cover” transaction to fund statutory tax withholding tied to vesting of restricted stock units, carried out under a Rule 10b5-1(c) trading plan and not a discretionary sale. After this tax-related sale, Parikh directly holds 272,713 shares of Humacyte common stock.
Humacyte, Inc. reported a net loss of $17.6 million for the quarter ended March 31, 2026, compared with net income of $39.1 million a year earlier, as favorable fair value movements on earnout and warrant liabilities were much smaller than in 2025.
Total revenue was $0.5 million, with product revenue from Symvess increasing to $493,000 while contract revenue declined. Operating expenses rose to $29.4 million, driven mainly by higher research and development spending of $19.5 million.
Humacyte used $25.1 million of cash in operating activities and ended the quarter with cash and cash equivalents of $48.5 million. Management states that these resources are not sufficient to fund operations beyond one year without stronger Symvess sales and/or additional financing, raising substantial doubt about the company’s ability to continue as a going concern.
Humacyte, Inc. received a Nasdaq notice that its common stock bid price was below the required $1.00 per share for 30 consecutive business days ended May 1, 2026, putting it out of compliance with Nasdaq Listing Rule 5450(a)(1).
The company has 180 calendar days, until November 2, 2026, for its closing bid price to be at least $1.00 per share for a minimum of 10 consecutive business days to regain compliance. Trading of the stock and the company’s operations and SEC reporting continue unchanged for now, but there is explicit delisting risk if compliance is not restored.
Humacyte, Inc. is asking stockholders at its virtual annual meeting on June 9, 2026 to approve six items, including electing three Class II directors and an advisory vote on executive pay and its frequency. Stockholders will also vote on ratifying PricewaterhouseCoopers LLP as auditor for 2026 and increasing authorized common stock from 350,000,000 to 550,000,000 shares via a charter amendment. Shares outstanding were 222,019,108 as of April 23, 2026, the record date. The proxy outlines governance practices, committee structures, and 2025 compensation, including bonuses paid at 80% of target and significant stock option and RSU grants to senior executives.
Humacyte, Inc. and Fresenius Medical Care have amended their 2018 distribution agreement for Symvess, an acellular tissue engineered vessel. Humacyte now has exclusive rights to distribute Symvess outside the U.S., while Fresenius Medical Care Holdings, Inc. will receive low-single-digit royalties on ex-U.S. net sales.
Existing terms for U.S. distribution remain unchanged. Fresenius Medical Care Holdings, Inc. and its parent, Fresenius Medical Care, report beneficial ownership of 18,312,735 shares of Humacyte common stock, representing 8.4% of the class, all with shared voting and dispositive power.
Humacyte, Inc. entered a Third Amendment to its distribution agreement with Fresenius Medical Care, giving Humacyte the sole right to develop, manage regulatory matters for, and commercialize its 6 millimeter acellular tissue engineered vessel, branded Symvess, on a worldwide basis.
In return, Humacyte will pay Fresenius low-single-digit royalties on net sales of Symvess outside the U.S., after a two-year royalty-free period following launch in each country, while existing U.S. royalty rates from mid-single digits to low double digits remain in place and Fresenius stays obligated to adopt Symvess as a standard of care where supported. Humacyte highlights that this realignment supports its planned international expansion and potential indication-specific partnerships, while Symvess currently holds FDA approval only for extremity vascular trauma and remains investigational for other uses.
Humacyte, Inc. is raising $20 million through a registered direct offering of 25,000,000 shares of common stock at $0.80 per share. After placement fees and expenses, net proceeds are expected to be about $18.4 million.
The cash will support commercialization of Symvess in the vascular trauma indication, a planned Biologics License Application supplement for a hemodialysis use, related Phase 3 activities, broader pipeline development, and general corporate purposes. The offering, led by institutional investors, is expected to close on or about March 20, 2026, subject to customary conditions.